As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies.
Amidst the distress caused by a cancer diagnosis, patients are left to sort through vast amounts of information, treatment options, and concerns around efficacy and side effects, while juggling other life activities.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
Dr. Timothy Showalter talks about how AI can be a powerful force in recommending treatment for cancer patients. He is Artera's chief medical officer and the company has built a digital pathology tool for prostate cancer patients.
Avenda Health, a startup focused on personalized prostate cancer care, recently received 510(k) clearance from the FDA for its cancer mapping platform. The platform uses a patient’s own diagnostic data to define the extent of the disease and create a cancer probability map with optimal treatment margins.
CAR-T has become increasingly recognized as an exciting and potentially paradigm-shifting treatment in the past five years. In fact, more than 10,000 patients have undergone this new treatment for certain types of leukemia, lymphoma and multiple myeloma.
With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The MedCity CONVERGE conference at the University City Science Center June 19 in Philadelphia will be the scene of a dynamic series of conversations around cancer treatment, precision medicine, value-based care and investment trends. It will spotlight industry experts, presentations from innovative startups and collaborations.
Engineering researchers at the University of Michigan have developed a battery-operated injectable computer with a radio antenna that can transmit data to a device located up to 12 inches outside of the body.
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
Patients with previously treated advanced renal cell carcinoma have a new treatment option with cabozantinib — a kinase inhibitor shown to improve overall survival compared to everolimus, as a Cleveland Clinic researcher noted at ASCO 2016 over the weekend.
Break down the silos. Take control of your provider data.
The FDA issued an alert about the drug on Monday, and in the warning it warned healthcare professionals that the drug is not approved for previously untreated chronic lymphocytic leukemia.
Oncora Medical's approach provides clinical decision support for radiation oncologists to reduce radiation toxicity and guide more personalized treatments.
Under the terms of the agreement, Onxeo is acquiring DNA Therapeutics for an upfront payment of nearly $1.85 million in common shares at deal closing.
Future topics will include lower back pain, ADHD and type 2 diabetes.
Medtronic takes over the OsteoCool device for treating cancers that metastasize to the spine, created by Baylis Medical.